🇫🇷·Jun 10Industry
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Publisher
C
Cellectis
France
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Cellectis
- Region
- France
- Scope
- Industry
- Published
- June 10, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on cellectis.com
Leave the platform to read the original full article on the publisher site.
Source: Cellectis
Scope: Industry
Related coverage